Will Pate

I mean, I get it - I was on the other side of this at GCP when I worked with the startups program there. The business imperative is to win workloads, and the more funding the bigger the workloads tend to be. The non-cash benefits of raising look better over time. Getting tempted to consider a one and done round.

Reading glasses might be done. The FDA just approved a once-daily eye drop called VIZZ that sharpens near vision in about 30 minutes and keeps it sharp for up to 10 hours. One drop. Each eye. Per day. That's it. The active ingredient is aceclidine, a compound first used back in 1975 to treat glaucoma. Scientists figured out it could be repurposed to gently shrink the pupil, creating a "pinhole effect" that pulls close-up text back into focus, the same trick your eye does when you squint. Unlike Vuity, the 2021 drop that came before it, VIZZ doesn't mess with your focusing muscles. So no blurry distance vision. No brow ache. No weird zoom effect. It was tested across more than 30,000 treatment days with no major complications. Cost is roughly $2 a day. This matters because presbyopia, the age-related slide that hits most people between 40 and 45, already affects more than 120 million Americans. By 2030, the World Health Organization expects around 2 billion people worldwide to have it. LENZ Therapeutics, the maker, started rolling out samples in October. The squint era is ending. Source: Ynetnews, FOX 26 Houston, Yahoo News